艾塞那肽在高糖和低糖条件下对INS-1细胞胰腺十二指肠同源盒表达和细胞凋亡的影响
[Abstract]:Objective to investigate the effects of isenapeptide 1 (GLP-1) analogue on the expression of pancreatic duodenal homologous box (PDX-1) and apoptosis in islet B cell line INS-1. Methods INS-1 cells were cultured in vitro and divided into normal control group, high glucose group, low glucose group, high glucose Isenapeptide intervention group, low glucose Isenapeptide intervention group and high glucose metformin intervention group. The apoptosis of INS-1 cells was detected by flow cytometry double staining and Tunel in situ. The expression of PDX-1 was detected by real-time PCR Western blotting and immunohistochemistry, respectively. Results the apoptotic index and apoptosis rate in high glucose group and low glucose group were significantly higher than those in normal control group (P < 0.01), but there was no significant difference between high glucose group and low glucose group (P value 0.05). The apoptotic index and apoptosis rate were significantly higher than those in the normal control group (P 0.05), but were significantly lower than those in the high glucose group (P 0.05), and the apoptotic index and the apoptosis rate in the low glucose isenapeptide group were significantly higher than those in the normal control group (P There was no significant difference in apoptosis index and apoptosis rate between high glucose and low glucose isenapeptide intervention group (P all 0.05), and there was no significant difference in cell apoptosis index and cell apoptosis rate between high glucose and low glucose isenapeptide intervention group (P all 0.05), while high glucose metformin intervention had no significant difference in cell apoptosis index and cell apoptosis rate between the high glucose and low glucose isenapeptide intervention groups (all P = 0.05). The apoptotic index and apoptosis rate were significantly higher in the group than in the control group (P < 0.05), but there was no significant difference between the two groups (P 0.05). The expression of PDX-1 in high glucose group and low glucose group was significantly lower than that in normal control group (P < 0.01), there was no significant difference between high glucose group and low glucose group (P0.05), and the expression of PDX-1 in high glucose and low glucose group was significantly lower than that in normal control group (P0.05), but significantly higher than that in high glucose group (P0.05). The expression of PDX-1 was significantly lower in the high glucose group than in the normal control group (P0.05), but significantly higher than that in the low glucose group (P0.05), and there was no significant difference in PDX-1 expression between the high glucose and low glucose isenapeptide intervention groups (P0.05). The expression of PDX-1 in high glucose metformin intervention group was significantly lower than that in normal control group (P0.05), but there was no significant difference between high glucose group and high glucose group (P0.05). Conclusion under the condition of high glucose and low glucose, Isenapeptide can inhibit the apoptosis of INS-1 cells and upregulate the expression of PDX-1.
【作者单位】： 宁夏医科大学总医院内分泌科;宁夏银川市中医医院针灸康复中心;
【基金】：宁夏回族自治区自然科学基金资助项目(NZ1240)
【分类号】：R587.1
【相似文献】
相关期刊论文 前10条
1 陈刚;;艾塞那肽治疗超重和肥胖2型糖尿病32例疗效观察[J];中外医学研究;2011年35期
2 李显丽;李奕平;王晓苓;;艾塞那肽治疗肥胖2型糖尿病的临床疗效观察[J];昆明医学院学报;2012年04期
3 胡玲;沈浩;;艾塞那肽治疗肥胖2型糖尿病23例临床分析[J];中国实用内科杂志;2012年04期
4 黄艾平;张弛;陈丹丹;赵乃蕊;李华珠;杨晓春;周桂莲;冯晶;王敏;吴文宇;熊璞;陈晶;王霞;;艾塞那肽治疗对2型糖尿病患者缓解期的影响研究[J];中国药房;2012年22期
5 李小囡;李可心;张英;;艾塞那肽治疗2型糖尿病的疗效观察[J];吉林医学;2012年34期
6 李可心;李春花;李远征;王虹;;艾塞那肽治疗肥胖2型糖尿病64例疗效观察[J];中国社区医师(医学专业);2012年36期
7 张颖;曾朝阳;刘旭;华思文;;艾塞那肽治疗2型糖尿病的临床观察[J];山西医科大学学报;2012年02期
8 金毅;;艾塞那肽治疗2型糖尿病患者的疗效观察[J];中外医疗;2012年21期
9 章玉华;蔡祥增;王雷;王德震;;艾塞那肽治疗2型糖尿病临床观察[J];临床合理用药杂志;2012年31期
10 杨璐;谢文秀;曹悦鞍;彭朝胜;夏菁;张文洛;;艾塞那肽治疗肥胖2型糖尿病临床观察[J];转化医学杂志;2012年02期
相关会议论文 前10条
1 丁丽;张绍维;赵文洲;罗晶;;艾塞那肽对人脐静脉内皮细胞内皮型一氧化氮合酶活性和表达的影响[A];中华医学会第十二次全国内分泌学学术会议论文汇编[C];2013年
2 陈若然;梁琳琅;王健美;王宇;;艾塞那肽对载脂蛋白E基因敲除小鼠动脉粥样硬化模型中动脉病变的作用[A];中华医学会第十二次全国内分泌学学术会议论文汇编[C];2013年
3 陈晶;张弛;陈丹丹;李华珠;杨晓春;周桂莲;王敏;熊璞;王霞;刘瑛;;艾塞那肽治疗对2型糖尿病患者缓解期的影响[A];中华医学会第十次全国内分泌学学术会议论文汇编[C];2011年
4 吴静;李骏;王全胜;刘晓丽;倪卫惠;邵晓丽;祝保艳;;艾塞那肽对2型糖尿病临床疗效观察[A];中华医学会第二届糖尿病及性腺疾病学术会议论文集[C];2012年
5 胡晶;马永文;;艾塞那肽在肥胖2型糖尿病患者中疗效和安全性的临床观察[A];中华医学会糖尿病学分会第十六次全国学术会议论文集[C];2012年
6 刘赛;张弛;陈丹丹;李华珠;杨晓春;周桂莲;王敏;熊璞;王霞;陈晶;刘瑛;;艾塞那肽治疗对血压正常2型糖尿病患者血压的影响[A];中华医学会第十次全国内分泌学学术会议论文汇编[C];2011年
7 王琛;李卫虹;王广;王海宁;冯新恒;高洪伟;洪天配;;艾塞那肽对2型糖尿病患者冠状动脉内皮功能的影响[A];中华医学会第十一次全国内分泌学学术会议论文汇编[C];2012年
8 王琛;李卫虹;王广;王海宁;冯新恒;高洪伟;洪天配;;艾塞那肽对2型糖尿病患者冠状动脉内皮功能的影响[A];中华医学会糖尿病学分会第十六次全国学术会议论文集[C];2012年
9 顾丽萍;张颖;顾鸣宇;严率;吴艺捷;;2型糖尿病患者加用艾塞那肽注射液治疗的临床观察[A];中华医学会糖尿病学分会第十六次全国学术会议论文集[C];2012年
10 李任远;邓洪容;许雯;李津;严晋华;杨黛稚;翁建平;;24周艾塞那肽治疗对新诊断2型糖尿病患者血糖及骨转化标志物的影响[A];中华医学会糖尿病学分会第十六次全国学术会议论文集[C];2012年
相关硕士学位论文 前10条
1 李海东;艾塞那肽合用CSII与单用CSII治疗对初发肥胖型T2DM患者临床疗效的对比研究[D];延边大学;2015年
2 张津晶;艾塞那肽通过抑制聚二磷酸腺苷核糖聚合酶1延缓糖尿病动脉粥样硬化的发展[D];山东大学;2015年
3 江雪舒;艾塞那肽不同注射次数治疗2型糖尿病的疗效对比[D];第三军医大学;2015年
4 沙吾丽.沙特江;艾塞那肽对糖尿病肾脏病合并肥胖患者的临床疗效观察[D];新疆医科大学;2015年
5 贾玉敏;艾塞那肽治疗初诊肥胖2型糖尿病合并OSAHS的临床观察[D];新疆医科大学;2015年
6 于宁;艾塞那肽对肥胖2型糖尿病患者肝脏脂肪含量及血清chemerin水平的影响[D];青岛大学;2015年
7 陈莹莹;艾塞那肽对糖尿病大鼠脂肪细胞脂代谢及脂肪因子表达的影响[D];南京大学;2013年
8 洪丽华;艾塞那肽治疗2型糖尿病的疗效分析和安全性评价[D];浙江大学;2016年
9 苏春;艾塞那肽对2型糖尿病患者炎症因子、脂联素及瘦素的影响[D];广西医科大学;2012年
10 韩文彪;艾塞那肽治疗2型糖尿病疗效的初步观察[D];青海大学;2011年
，本文编号：2137806
本文链接：https://www.wllwen.com/yixuelunwen/nfm/2137806.html
